高表达P73基因抑制肺腺癌细胞VEGF、bFGF mRNA表达

目的　观察高表达的p73基因对肺腺癌细胞生长曲线以及血管内皮生长因子 (VEGF)、碱性成纤维细胞生长因子 (bFGF)mRNA表达水平的影响 ,探讨高表达 p73基因在肺腺癌血管生成中的作用。 方法　将 p73α、p73 β以脂质体法转染A5 49细胞、H12 99细胞 ,采用细胞计数法绘制转染前后两种细胞生长曲线 ,RT PCR法半定量分析转染前后两种细胞中VEGF、bFGFmRNA的表达水平的变化。结果　转染p73基因后 ,A5 49细胞、H12 99细胞生长受到抑制 ,VEGF、bFGFmRNA表达水平下降 ,较未转染 p73基因的细胞有显著性差异 (P <0 .0 5 ) ,其中 p73 β对VEGFmRNA表达的抑制作用更为显著 (P <0 .0 1)。 结论　高表达的 p73基因能够抑制肺腺癌细胞生长 ,降低肺腺癌细胞中VEGF、bFGFmRNA表达水平 ,提示高表达的 p73基因可能参与调控人肺腺癌VEGF和bFGF基因表达 ,从而起到一个抑癌基因的作用     

诺维本联合放射对人肺腺癌细胞的杀伤作用

[目的]研究诺维本联合放射对人肺腺癌细胞(PAA)的杀伤作用.[方法]应用四唑盐比色试验(MTT)检测诺维本对PAA细胞生长的抑制率和时间效应;流式细胞术检测细胞周期及凋亡情况.[结果]不同浓度(20、40、60、80、100μmol/L)的诺维本作用24h后对细胞生长的抑制率分别为6.12%、18.80%、53.91%、77.10%和90.20%,ID50为59.10μmol/L;诺维本对细胞生长的抑制作用在高浓度时具有明显的时间依赖性;从流式细胞术的细胞周期分析结果发现,经诺维本作用后G2/M期细胞的比例明显增加;单纯药物组的凋亡在24h出现,单纯放射组在放射后12h出现明显的凋亡小峰,药物放射联合组出现凋亡的时间更早,凋亡峰亦更明显,各组细胞在不同时间内的平均凋亡百分数分别为:对照组5.362±4.123,单纯放射组6.523±6.214,单纯药物组9.985±9.023,药物联合放射组18.100±8.965,药物联合放射组与其它3组相比,P均＜0.05.[结论]诺维本联合放射对人肺腺癌细胞有协同杀伤作用.     

Experimental Study of Anti-tumor Effect of Baofeixiaoliu Capsule on Lung Adenocarcinoma

背景与目的:研究保肺消瘤胶囊的抗肺癌作用。材料与方法:应用体外细胞抑瘤模型及荷瘤裸鼠抑瘤模型研究该药的抗肿瘤作用。结果:通过荷瘤(肺腺癌)裸鼠的药效学研究表明,保肺消瘤胶囊在剂量80-320 mg/kg范围内,有较好的抑癌效果,其抑癌率达48％以上,其中160 mg/kg剂量的抑瘤效果接近于5-Fu的抑瘤效果。体外人肺腺癌细胞模型的观察结果,亦证实了保肺消瘤胶囊有较好的抑制癌细胞增长的效果,使细胞生长速度减缓,有丝分裂指数减低,并使细胞结构破坏。体外实验结果与动物模型的结果相一致。结论:体外及体内实验表明保肺消瘤胶囊具有较好的抑瘤作用。     

Symptoms of Early Cancer Especially Barrett''''s Carcinoma

The incidence of the adenocarcinoma of the esophagus (AC) has been rising exponentiallyin the Western World within the last 30 years.The reasons for this increase are not yet understood.Massive and long lasting gastroesophageal reflux causes the Barrett's esophagus which is considered tobe a precaneerosis.Therefore early diagnosis and appropriate treatment of gastroesophageal reflux isessential for the prevention of this tumor.This makes heartburn the leading clinical symptom in thepatient's history.In patients with heartburn it is possible to early endoscopically diagnose a Barrett'sesophagus or adenocarcinoma of the esophagus.However only few patients with this increased risk receivean index-endoscopy.In clinical studies a high rate of early carcinomas could be found and could be treatedwith mueosectomie or ablation.The majority of patients with AC present with symptoms suggestive ofprogressed disease such as dysphagia or weight loss.The prognosis in patients in late disease stages are witha 5-year survival of only 30% far worse than in patients with early carcinoma (85%).However the earlysymptoms such as heartburn or regurgitation are unspecific and make an effective diagnostical strategydifficult.To optimize screening it would be beneficial to identify patients with high risk for the developmentof adenocarcinoina of the esophagus.     

Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus–Di?erences in Etiology, Epidemiology and Prevention

Incidence of esophageal carcinoma With more than 300 000 new cases per year, cancerof the esophagus, predominantly squamous cell carcinoma(SCC), is one of the 10 most frequently diagnosed tumortypes. Esophageal cancer occurs often in developing coun-tries and shows great regional di?erences[1]. While in re-cent history the incidence of SCC has decreased slightly inregions of high risk and stayed constant in the USA andWestern Europe, the rate of adenocarcinoma of the esoph-agus (AC) has…     

38例肺源性脑转移瘤临床病理分析

目的 肺源性脑转移瘤临床病理特征。方法 研究38例肺源性脑转移瘤的临床和病理特点,男性27例,女性11例;年龄在30-74岁之间。其中5例转移性癌作免疫组织化学染色和电镜观察。结果 20例为腺癌,12/20为乳头状腺癌;5例为腺鳞癌,7例为鳞形细胞癌,4例为燕麦细胞癌,2例为不典型类癌;5例乳头状腺癌作免疫组织化学染色示CK(5/5)和CEA(4/5)为阳性;电镜显示转移性乳头状腺癌具有肺泡Ⅱ型上皮细胞分化潜能。结论 肺癌中腺癌更易发生脑转移,免疫组织化学在鉴别诊断中有一定的辅助作用,转移性乳头状腺癌具有异质性。     

天地欣(国产香菇多糖)配合化疗治疗中晚期胃肠道腺癌72例临床观察

用国产香菇多糖（天地欣）配合化疗治疗中晚期胃肠道腺癌40例与32例未加用香菇多糖的同种治疗病例比较发现，香菇多糖对增强患者的免疫功能很有效（P＜0．01），短期内对提高化疗的总缓解率帮助不大（P＞0．05），对降低化疗的毒副反应及改善生活质量有一定影响。香菇多糖（天地欣）的毒副反应小，疗效确切。     

The therapeutic effect of intratumoral injection of GM-CSF gene-modified allogenic macrophages on tumor-bearing mice

Both the antigen presenting ability and the cytotoxicity of macrophages can be enhanced by GM-CSF gene transfer. In the present study, the therapeutic effect of intratumoral injection with GM-CSF gene-modified allogenic macrophages on tumor-bearing mice observed. The peritoneal macrophages of C57BL/6 mice were transfected with GM-CSF gene mediated by recombinant adenovirus and the subcutaneous CT26 colon adeno-carcinoma-bearing BALB/c mice were treated by intratumoral injection of the above macrophages. The survival time of the tumor-bearing mice were prolonged significantly and some tumor mass disappeared completely. The necroses of the tumor cells and massive infiltration of inflammatory cells were observed 6 days after treatment 30 days after treatment, only the leftover of tumor cells and the inflammatory cells remained. The data indicated that introtumoral injection of GM-CSF gene-modified allogenic macrophages displayed more potent therapeutic effect on the preestablished tumor-bearing mice. Supported by National High Biotechnology Foundation (Z20-01-03). This is one of papers of the special issue on gene therapy research (Chin J Cancer Res Vol. 9 No. 4 December, 1997).     

Cutaneous metastases from adenocarcinoma of unknown primary

Cutaneous manifestations of malignancy are not uncommon, especially in advanced disease. They may also occur early in malignant disease or they may even signify recurrence particularly if they are paraneoplastic in nature. Clinical diagnosis can be difficult because of the wide spectrum of appearance of these lesions, and, in many cases, because of the lack of an identifiable underlying primary. Presented here is the case of a 65-year-old woman with multiple inflammatory cutaneous metastases, which were sclerodermoid in nature. These appeared 14 months after initial diagnosis of adenocarcinoma of unknown primary (ACUP) and signified the beginning of a rapid deterioration in her condition. The coexistence of limited systemic sclerosis (scleroderma) and ACUP initially raised several interesting diagnostic possibilities. Adenocarcinoma of unknown primary and the sclerodermoid reaction in malignancy are discussed.     

Stage IV ovarian clear cell adenocarcinoma treated effectively by chemotherapy with etoposide and cisplatin (EP)

We report a case of stage IV ovarian clear cell adenocarcinoma (OCCA) in a 72-year-old woman who was treated postoperatively with etoposide combined with cisplatin (EP). The patient exhibited bulky intrapelvic and para-aortic lymph nodes with metastases to the cervical lymph nodes. The primary lesion was resected and, postoperatively, she received one course of combination chemotherapy consisting of cyclophosphamide, 500 mg/m²; doxorubicin, 50 mg/m²; and cisplatin, 70mg/m² (CAP), followed by six courses of combination chemotherapy consisting of etoposide, 80mg/m² days 1 through 5 and cisplatin, 70 mg/m² on day 5 every 4 weeks. After five courses of EP, the lymph node metastases had virtually disappeared. The patient is now disease-free 21 months after the initial surgery. These findings suggest that EP may be useful in treating OCCA.